ANI Pharma plans Delaware Supreme Court appeal in CG Oncology dispute
ANIP•ANI Pharmaceuticals to appeal Delaware ruling
ANI Pharmaceuticals will appeal to the Delaware Supreme Court after a trial judge denied its post-trial motions in a dispute with CG Oncology.
The company sought a new trial plus judgment as a matter of law on an unjust enrichment claim tied to assets sold to CG Oncology in 2010.
ANI is pursuing recovery of the assets’ value, including a claimed 5% running royalty on future worldwide sales of cretostimogene grenadenorepvec.
